You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Srinivas Akkaraju

Professional at Samsara Biocapital LLC
Overview
Relationships
In The News
Paths
Education
Career History
Boards & Committees
Political Donations
Investments
Public Holdings
Transactions
Awards & Honors

Srinivas Akkaraju

Professional at Samsara Biocapital LLC

Overview

Age
49 (Born 1969)
Notable Companies
Panorama Capital LLC
Awards
2
Board Seats
21
Number of Relationships
This person is connected to 644 people.

Relationships See Details


Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Co-Founder at Baker Bros. Advisors LP

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Director at Sarcoma Foundation of America

Co-Founder at Panorama Capital LLC

President, Chief Executive Officer, Chief Financial Officer & Director at Versartis, Inc.

President at Sofinnova Ventures, Inc.

General Partner at Benhamou Global Ventures LLC

President, Chief Financial Officer, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc.

Partner at New Leaf Venture Partners LLC
See 634 more listings with RelSci Professional.

In The News See More

ENP Newswire
August 11, 2017
Business Wire
June 12, 2017
peHUB
March 22, 2017
RelSci
September 7, 2016
Business Wire
March 31, 2015
See full news coverage and complete stories with RelSci Professional.

Paths to Srinivas Akkaraju

Srinivas Akkaraju
You
Connections via Relationship Science
Srinivas Akkaraju
Sync your contacts to see how you can connect with Srinivas Akkaraju.

Educational Background

MD in Immunology 
A LEADER IN THE BIOMEDICAL REVOLUTION, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.
BA in Computer Science 
Rice University is a comprehensive research university that fosters diversity and an intellectual environment that produces the next generation of leaders and advances tomorrow’s thinking and is set in the heart of Houston, Texas, the nation’s fourth-largest city.

Career History

Professional
2016 - Current
Senior Advisor
2013 - Current
Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.
Managing Director
2009 - 2013
New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools. The firm provides financing for early and later stage capital requirements and invests in both public & private companies.
Partner
2001 - 2006
J.P. Morgan Partners provides financing for growth capital, corporate acquisitions, LBOs, special situations and recapitalizations. The firm invests globally across a variety of sectors including consumer, media, energy, industrial, financial services, healthcare and technology
Co-Founder
Prior
Panorama Capital focuses on investments in the life sciences and technology industries. The firm looks for companies with exceptional management teams and the potential to become market leaders in their industries. They invest in companies from the seed stage to later-stage companies with more established businesses. Within the life sciences sector, Panorama Capital focuses on companies that are developing therapeutics that address significant unmet medical needs and that have a well-defined mechanism of action and clinical/regulatory strategy. The firm's technology investments focus on companies with business models that are operating in sectors in which the firm has significant domain expertise. Panorama Capital's investments typically range from $6 million to $18 million over the life of a company
Partner
Prior
Sofinnova Venture Partners IX LP invests in life science and technology companies located in the US and Europe. The fund targets companies operating in the fields of health care, clinical stage drug development, biopharmaceutical products, components, systems, and software. Its investment size ranges from $15 to $30 million in life science companies with an initial commitment of $5 - $15 million and for technology companies it invests $5 - $15 million over the life of a company with an initial investment size of $3 - $5 million. It provides financing for seed, early and later stage capital requirements. It makes seed stage investments from $0.1 - $1 million to incubate promising technologies out of academia or industry.
Business & Corporate Development
Prior
Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases and opportunistic areas. The company was founded by Herbert W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Boards & Committees

Corporate Boards ▾
Director
2017 - Current
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Member, Board of Directors
2015 - Current
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.
Chairman, Board of Directors
2013 - Current
Versartis, Inc. engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.
Member, Board of Directors
2012 - Current
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Member, Board of Directors
2003 - Current
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Director
Current
Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. It focuses on tumor-selective adaptive responses, metastatic disease, and cancer evasion pathways such as immuno-oncology. The company was founded by Amato Giaccia and Albert Koong on July 25, 2007 and is headquartered in San Francisco, CA.
Senior Advisor
Current
Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.
Member, Board of Directors
Current
Principia Biopharma, Inc. is a biopharmaceutical company focused on the design and development of small molecule drugs within the fields of autoimmune disease and oncology that are potent, safe, and have antibody-like specificity for its targets. The firm's discovery and development platform comprises a collection of capabilities to expedite the drug discovery and development process. Its platform produces compounds with selectivity, enabling development of multiple product candidates with substantial commercial potential. The company was founded by Jack Taunton an Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.
Independent Director
2014 - 2015
ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA.
Director
Prior - 2011
Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics.It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to:1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.
Independent Director
2011 - Prior
Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded on November 2, 2011 and is headquartered in Lexington, MA.
Director
2008 - 2009
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The company's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Independent Director
2006 - 2011
Pharmos Corp. discovers and develops therapeutics to treat diseases of the nervous system, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. It develops Dextofisopam, Tianeptine and Cannabinor. The company was founded by Haim Aviv in 1990 and is headquartered in Iselin, NJ.
Director
2005 - 2010
Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection.The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.
Director
2002 - 2008
Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ
Director
Prior
Eyetech Pharmaceuticals, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.
Director
Prior
PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.
Director
Prior
Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668, and PPI-383 for treating hepatitis C virus infections. The company was founded in March 2006 by Omar K. Haffar, Antoun Nabhan and David V. Jobes and is headquartered in San Francisco, CA.
Director
Prior
Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA.
Director
Prior
Non-Profit Boards ▾
Director
Current
The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia.

Political Donations

$1,300
2010
$1,400
2009
$1,000
2008
$350
2004
$325
2003

Investments

Details Hidden
PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.

Public Holdings

Restricted data only for RelSci Professional users.

Transactions

Details Hidden
Sofinnova Venture Partners IX LP raised money in a private placement transaction

Awards & Honors

Rank #84
2007
Forbes Magazine - The Midas List
Sponsored by
Rank #82
2006
Forbes Magazine - The Midas List
Sponsored by

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.